# DRUG DISCOVERY MODEL USING MACHINE LEARNING

**A PROJECT REPORT**

***Submitted by***

Dishita Chaturvedi (23BAI10104)
Aanchal Rathi (23BAI10110)
Prisha (23BAI10881)
Smriti Singh (23BAI11385)
Vikash Kumar (23BAI11396)

*in partial fulfillment for the award of the degree of*

**BACHELOR OF TECHNOLOGY**

*in*

**COMPUTER SCIENCE AND ENGINEERING**


**School of Computing Science Engineering and Artificial Intelligence**

**VIT BHOPAL UNIVERSITY KOTHRIKALAN, SEHORE MADHYA PRADESH – 466114**

December 2024

# BONAFIDE CERTIFICATE

Certified that this project report titled **"Drug Discovery Using ML"** is the bonafide work of "**Dishita Chaturvedi (23BAI10104), Aanchal Rathi (23BAI10110) , Prisha (23BAI10881) , Smriti Singh (23BAI11385) and Vikash Kumar (23BAI11396)**" who carried out the project work under my supervision. Certified further that to the best of my knowledge, the work reported here does not form part of any other project/research work on the basis of which a degree or award was conferred on an earlier occasion on this or any other candidate.

**Dr. Nikhil Pateria**
**PROJECT SUPERVISOR**
School of Computing Science Engineering and Artificial Intelligence
VIT BHOPAL UNIVERSITY

The Project Exhibition I Examination is held on _____

# ACKNOWLEDGEMENT

First and foremost I would like to thank the Lord Almighty for His presence and immense blessings throughout the project work.

I wish to express my heartfelt gratitude to the **Program Chairs**, for much of their valuable support and encouragement in carrying out this work.

I would like to thank my internal guide, **Dr. Nikhil Pateria**, for continually guiding and actively participating in my project, and giving valuable suggestions to complete the project work.

I would like to thank all the technical and teaching staff of the Health Informatics, who extended directly or indirectly all support.

Last, but not the least, I am deeply indebted to my parents who have been the greatest support while I worked day and night for the project to make it a success.

# LIST OF ABBREVIATIONS

| S.No. | ABBREVIATION | FULL FORM |
|---|---|---|
| 1 | ML | Machine Learning |
| 2 | DL | Deep Learning |
| 3 | GNN | Graph Neural Network |
| 4 | ReLU | Rectified Linear Unit |
| 5 | RF | Random Forest |
| 6 | RC | Random Classifier |
| 7 | SMILES | Simplified Molecular Input Line Entry System |
| 8 | CheMBL | Chemical Database of Bioactive Molecules |
| 9 | PRC | Precision Recall Curve |
| 10 | CNN | Convolutional Neural Networks |
| 11 | RNN | Recurrent Neural Networks |
| 12 | SVM | Support Vector Machines |

# LIST OF FIGURES

# ABSTRACT

Drug discovery, a cornerstone of modern medicine, is a long, complex, and resource-intensive process. Developing a new drug typically involves identifying bioactive compounds, optimizing their chemical properties, and validating their efficacy in biological systems. However, traditional methods of drug discovery rely heavily on wet-lab experimentation, which is costly, time-consuming, and often hindered by the low hit rates of identifying effective candidates. With the vast chemical space of potential molecules estimated at over 106010^{60}1060, exhaustive experimental exploration is practically impossible. This bottleneck has necessitated the development of computational models that can predict molecular bioactivity with speed and accuracy, narrowing down potential candidates for further experimental validation.

Existing research has focused on leveraging machine learning and deep learning models to address this problem. Random classifiers and graph neural networks (GNNs) are two prominent approaches that have been explored. Random classifiers, while simplistic, offer a baseline for performance evaluation, providing insights into the randomness inherent in the data. On the other hand, GNNs, which treat molecules as graph structures, represent a paradigm shift by allowing intricate modeling of molecular relationships, such as atom connectivity and bond types. Despite these advancements, challenges remain in generalizing models across diverse chemical datasets, interpreting predictions, and efficiently handling high-dimensional data.




Fig 0.1 Drug-Target Interaction Visualization

In our work, we aimed to address the need for efficient and interpretable drug discovery pipelines by exploring and comparing two models: a Random Classifier and a GNN-based molecular prediction model. The Random Classifier served as a foundational baseline to assess how far purely random predictions can go in differentiating bioactive compounds from inactive ones. This allowed us to set a lower bound for model performance and appreciate the nuances of the data distribution. Building on this, we designed a GNN model to leverage the graph-like nature of molecular data, which captures the structural and relational properties of molecules more effectively than traditional flat feature representations.

Through this comparative approach, we sought to answer critical questions: How much value do graph-based models add over baseline methods in drug discovery? Can they generalize well to novel compounds, or are their predictions confined to known data distributions? These questions guided our journey as we constructed a robust computational pipeline for molecule-based predictions. By combining domain knowledge, machine learning techniques, and interpretability tools, we believe this work not only contributes to the ongoing research in drug discovery but also highlights the potential for multidisciplinary approaches to accelerate breakthroughs in this essential field.

# TABLE OF CONTENTS

# CHAPTER 1 INTRODUCTION

## 1.1 Introduction

Our project is an ML model designed to streamline the drug discovery process by predicting bioactivity and identifying potential drug candidates. Using GNNs and random classifiers, the model analyses molecular structures as graphs to capture complex relationships within the data. This approach aims to reduce the time and cost associated with traditional drug discovery methods, accelerating the identification of effective drug candidates for various diseases.

## 1.2 Motivation for the work

The motivation for this project arises from the significant challenges in the pharmaceutical industry, where drug discovery is an expensive and time-consuming process. Traditional methods involve labour-intensive laboratory experiments, preclinical testing, and clinical trials, often leading to high failure rates and delayed drug development. This inefficiency, combined with the enormous volume of molecular compounds to screen, makes it difficult to identify viable drug candidates quickly and cost-effectively. The industry's key challenges include the high costs of research, the limited predictive accuracy of current computational models, and the inability to efficiently handle large datasets. In response, we aimed to leverage machine learning, particularly graph neural networks (GNNs), to accelerate the drug discovery process. By modeling molecules as graphs, GNNs can capture complex relationships between molecular structures and biological targets, improving predictions of bioactivity. This approach not only promises to reduce the time and resources required for screening but also holds the potential to revolutionize the drug development pipeline, enabling faster, more cost-effective identification of promising drug candidates and ultimately improving the accessibility of new treatments.

## 1.3 Problem Statement

Traditional drug discovery is costly, slow, and inefficient in predicting viable drug candidates, often resulting in high failure rates. This project leverages graph neural networks (GNNs) to predict molecular bioactivity, enhancing the speed and accuracy of drug screening and reducing

overall development costs. By modeling molecules as graphs, the approach aims to accelerate the identification of promising drug candidates, ultimately improving the efficiency of the drug discovery pipeline.

## 1.4 Objective of the work

The objectives of this project are as follows:

- Develop a machine learning model using graph neural networks (GNNs) to predict molecular bioactivity.
- Accelerate the drug discovery process by improving the speed and accuracy of drug candidate identification.
- Reduce costs associated with traditional experimental drug screening methods.
- Utilize molecular graph representations to capture complex chemical interactions for more accurate predictions.
- Optimize the model for scalability, allowing it to handle large molecular datasets efficiently.
- Provide insights into molecular structure-activity relationships to aid in drug design and development.

## 1.5 Organization of the report

The report is structured as follows: Chapter 1 provides an overview of the technologies used in the project. Chapter 2 discusses the various existing works like that of the project. Chapter 3 discusses the proposed system addressing the existing problems. Chapter 4 details the implementation and system architecture of the project. Chapter 5 discusses work done and observations of the application. Chapter 6 covers the future enhancements that can be done to the project along with a summary of the achievements and the impact of our work.

## 1.6 Summary

This project aims to leverage machine learning, specifically GNNs, to predict molecular bioactivity, significantly accelerating the drug discovery process. By utilizing molecular graph

representations, the model enhances the accuracy of identifying promising drug candidates while reducing the high costs and time traditionally associated with experimental drug screening. The approach offers deeper insights into the structure-activity relationships of molecules, optimizing drug development efficiency and potentially opening new avenues for the discovery of effective therapeutic agents.

# CHAPTER 2 LITERATURE SURVEY

## 2.1 Introduction

Traditional drug discovery is a complex and resource-intensive process that involves several stages, including target identification, screening, and optimization of lead compounds. These stages are often slow, expensive, and require extensive laboratory work, leading to significant financial burdens and delays in bringing new drugs to market. The advent of computational techniques has introduced the possibility of using machine learning models to predict molecular properties and interactions, enabling faster and more cost-effective drug discovery. Among these models, graph neural networks (GNNs) have shown promise due to their ability to represent molecules as graphs, where atoms are nodes and chemical bonds are edges. This structure allows GNNs to effectively capture the relationships and properties of molecules, providing a powerful tool for predicting their biological activity. By leveraging GNNs, researchers can screen vast chemical libraries, identify potential drug candidates, and understand their interactions with biological targets, significantly accelerating the drug discovery process and reducing costs.

## 2.2 Core Area of the Project

The core area of the Drug Discovery project focuses on two main components:

- **Machine Learning for Drug Activity Prediction:** This involves utilizing advanced machine learning models, specifically Graph Neural Networks (GNNs), to analyse molecular structures and predict their biological activity. By processing molecular graphs, these models can identify potential drug candidates and their interactions with specific targets, thus aiding in the early stages of drug discovery.
- **Model Improvement through Visualization:** While the primary focus is on predictive modeling, the project also emphasizes improving model interpretability. This is achieved through techniques like activation heatmaps and molecular fingerprints, which help enhance the understanding of the model's decision-making process and provide valuable insights into the underlying biology.

## 2.3 Existing Algorithms

### 2.3.1 Algorithm 1- Graph Neural Networks (GNNs) for Molecular Activity Prediction

One of the most promising techniques in drug discovery is the use of GNNs for predicting the biological activity of molecules. GNNs model molecular structures as graphs, where atoms are nodes and chemical bonds are edges. These models are highly effective because they can capture complex relationships and interactions between atoms and molecules. By training on large datasets of molecular graphs and their known biological activity, GNNs can learn to predict how new molecules might interact with specific biological targets, enabling the identification of potential drug candidates. This approach has the potential for superior accuracy, particularly in identifying non-obvious drug-target interactions that traditional methods might miss. Recent advancements in GNNs, like the use of attention mechanisms and message-passing algorithms, have further enhanced their ability to model molecular properties with high precision.

### 2.3.2 Algorithm 2- Random Forest for QSAR Modeling

Quantitative Structure-Activity Relationship (QSAR) modeling is a widely used method in drug discovery to predict the biological activity of compounds based on their chemical structure. Random Forest, an ensemble learning method, is frequently applied in QSAR studies. It works by constructing multiple decision trees based on random subsets of features and samples, and then combining their outputs to produce a more robust prediction. In the context of drug discovery, Random Forest has been employed to predict properties such as toxicity, solubility, and drug efficacy. The key advantage of Random Forest in QSAR modeling is its ability to handle large and complex datasets, manage missing data, and provide feature importance, which helps identify key chemical features responsible for the activity. Despite its strengths, the interpretability of Random Forest models remains a challenge, limiting their use in some drug discovery applications.

### 2.3.3 Algorithm 3- Deep Learning Models for Drug Discovery

Deep learning models, particularly Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs), have also shown great promise in drug discovery. CNNs are often used to process molecular images or 3D molecular structures, identifying patterns in the spatial arrangement of atoms that correlate with biological activity. RNNs, on the other hand, are suited for modeling sequences of molecular properties, such as peptide sequences or DNA/RNA, to predict their activity against disease targets. These deep learning models are capable of automatically extracting high-level features from raw data, significantly reducing the need for manual feature engineering. Although deep learning models can achieve high accuracy, they require large amounts of labeled data and computational resources, which can be a limitation in early-stage drug discovery.

### 2.3.4 Algorithm 4- Support Vector Machines (SVMs) for Classification in Drug Discovery

Support Vector Machines (SVMs) have been applied to a variety of classification tasks in drug discovery, such as predicting drug toxicity or classifying molecules based on their interaction with specific receptors. SVMs work by finding a hyperplane that best separates the data into different classes. In drug discovery, SVMs are particularly useful for binary classification problems, such as determining whether a molecule will exhibit activity against a target or not. One advantage of SVMs is their ability to handle high-dimensional data, such as molecular fingerprints or chemical descriptors, with relatively small training sets. However, SVMs can struggle with highly imbalanced datasets, which are common in drug discovery, and may require extensive tuning of hyperparameters to achieve optimal performance.

## 2.4 Observations from Literature Survey

The literature survey reveals that machine learning (ML) and deep learning (DL) techniques are becoming crucial in drug discovery, particularly for predicting molecular activity and drug-target interactions. Graph Neural Networks (GNNs) and Random Forests are effective for tasks like QSAR modeling, but challenges such as lack of interpretability and high computational

costs persist. While deep learning models like CNNs and RNNs show promise, they require large datasets and significant computational power. Overall, these advanced models are advancing drug discovery, but issues like data requirements and model transparency need further attention.

## 2.5 Summary

In summary, the integration of machine learning and deep learning into drug discovery is transforming how researchers predict molecular properties and interactions. While techniques like Graph Neural Networks, Random Forests, and Convolutional Neural Networks have shown great promise in various applications, challenges such as data availability, model interpretability, and computational resources remain. These advancements are enabling faster and more accurate drug discovery processes, but further work is needed to improve model transparency and reduce resource dependency, making these approaches more accessible and effective in real-world applications.

# CHAPTER-3 SYSTEM ANALYSIS

## 3.1 Introduction

System analysis in this project focuses on understanding the underlying components and processes involved in the drug discovery model, which combines machine learning with computational chemistry. The analysis aims to identify key factors influencing the model's performance, such as the quality and structure of input data, model architecture, and the methods used for training and evaluation. By systematically evaluating each aspect of the system, we can optimize the design and ensure that the model effectively predicts bioactivity, identifies drug candidates and provides actionable insights for further research. This step is crucial to refine the overall workflow and enhance the model's accuracy, efficiency, and scalability.

## 3.2 Problems

The following problems have been identified within the context of drug discovery:

- **Data Quality and Availability:** Incomplete or noisy data from sources like the ChEMBL database can negatively impact model performance, making preprocessing and feature engineering more challenging.
- **Model Complexity and Overfitting:** Balancing the complexity of the model is crucial. Deep learning models may lead to overfitting if not properly regularized, limiting their ability to generalize to new data.
- **Feature Selection:** Identifying relevant molecular features for predicting bioactivity remains difficult, and irrelevant features can reduce model performance.
- **Interpretability:** Machine learning models, especially complex ones, lack transparency, making it difficult to understand how predictions are made, which is crucial for model trust in drug discovery.

These are the key issues that need to be addressed for enhancing the effectiveness of the model in drug discovery tasks.

## 3.3 Proposed System

The proposed system aims to leverage machine learning techniques, specifically graph neural networks (GNNs), to improve drug discovery by predicting the bioactivity of molecules. The system utilizes molecular data, represented as graphs, where nodes correspond to atoms and edges represent bonds between them. By applying GNNs, the system can capture complex relationships and structural patterns that are critical for understanding molecular interactions. Additionally, a robust preprocessing pipeline will ensure data quality by cleaning and transforming raw bioactivity data. The system also incorporates model explainability techniques, such as SHAP values, to enhance interpretability and trust in predictions, ensuring that the results can be understood and validated by researchers in the pharmaceutical industry. This approach promises to significantly streamline the drug discovery process, reducing time and costs associated with traditional methods.

## 3.4 Summary

The project focuses on developing a machine learning model to predict molecular bioactivity, leveraging graph neural networks (GNNs). The main challenges include processing complex molecular data, selecting suitable algorithms, and ensuring model explainability. By addressing issues such as data complexity and the need for high-quality labeling, the system aims to improve prediction accuracy in drug discovery. The proposed approach combines cutting-edge techniques to predict bioactivity more efficiently, offering a promising solution for faster identification of potential drug candidates.

# CHAPTER- 4 SYSTEM IMPLEMENTATION

## 4.1 Introduction

The goal of the system implementation is to build an ML model capable of predicting molecular bioactivity. This involves developing and training an ML model that can process molecular data, identify meaningful patterns, and make accurate predictions. The implementation focuses on selecting suitable algorithms, fine-tuning the model, and evaluating its performance using metrics such as accuracy, precision, and recall. Key steps include data preprocessing, feature extraction, model selection, training, and testing to ensure the model's effectiveness in drug discovery applications.

## 4.2 Methodology

The methodology for the project is structured to ensure the development of an effective machine learning model for predicting molecular bioactivity in drug discovery. The following steps outline the approach:

1. **Data Collection and Preprocessing**:
    - **Dataset Selection**: Molecular data, including SMILES strings, is collected from reputable sources such as ChEMBL or PubChem.
    - **Data Preprocessing**: The data is cleaned and preprocessed to convert SMILES strings into graph-based representations, using techniques like one-hot encoding for atoms and bonds. The dataset is then split into training, validation, and test sets.
2. **Feature Engineering**:
    - **Graph Representation**: Molecular structures are represented as graphs where atoms are nodes, and bonds are edges. This allows the model to capture both structural and chemical information.
    - **Feature Extraction**: Features such as atom types, bond types, and molecular fingerprints are extracted to enhance the model's predictive capability.
3. **Model Development**:

- **Model Selection**: A graph-based neural network model, such as Graph Convolutional Networks (GCN) or Graph Neural Networks (GNN), is chosen to process the molecular graphs and learn the relationships between atoms and bonds that are crucial for predicting bioactivity.
- **Model Architecture**: The model architecture consists of multiple layers of graph convolution, followed by global pooling layers to aggregate the node-level predictions into a molecule-level output.

4. **Training the Model**:
    - **Loss Function**: A suitable loss function (e.g., binary cross-entropy) is chosen depending on the task (e.g., classification or regression).
    - **Optimization**: The model is trained using optimization algorithms like Adam or SGD, with hyperparameters like learning rate, batch size, and number of epochs tuned through experimentation.
5. **Model Evaluation**:
    - **Performance Metrics**: The model's performance is evaluated using metrics such as accuracy, precision, recall, F1 score, and ROC-AUC to assess its ability to predict molecular bioactivity effectively.
    - **Validation and Testing**: The trained model is validated and tested on separate datasets to ensure generalizability and robustness.
6. **Model Optimization**:
    - **Hyperparameter Tuning**: Grid search or random search is applied to optimize hyperparameters such as learning rate, hidden layer size, and dropout rate.
    - **Model Refinement**: Techniques like regularization (e.g., L2 regularization) and batch normalization are used to prevent overfitting and improve model robustness.
7. **Model Deployment and Analysis**:
    - **Result Interpretation**: The final model's predictions are analyzed to determine its effectiveness and potential areas of improvement.
    - **Visualization**: Visualizations of model activations, molecular fingerprints, and performance metrics are generated to understand how the model interprets molecular structures and predicts bioactivity.




Fig 4.1 Machine Learning Workflow for Drug Discovery

## 4.3 Project Procedure

The system design and architecture of the machine learning model for drug discovery are focused on creating an efficient, scalable, and interpretable framework for predicting molecular bioactivity. The architecture is built around a graph-based neural network model that leverages the structure of molecules to make accurate predictions.

### 4.3.1 System Design

The system is designed to process molecular data in the form of graphs, where each molecule is represented by a graph with atoms as nodes and bonds as edges. The input to the system is molecular data, typically in the form of SMILES strings, which are converted into graph representations. The model processes these graphs through multiple layers of graph convolution to extract relevant features, capturing both the chemical and structural properties of the molecules.

### 4.3.2 Model Architecture

At the core of the system is a Graph Neural Network (GNN) that performs graph convolution operations. The architecture includes multiple graph convolution layers (e.g., GCN layers), followed by a global pooling layer that aggregates information from the entire molecule into a single vector representation. This vector is then passed through a fully connected layer, which outputs a prediction (e.g., probability of bioactivity). The model architecture is designed to be modular, with flexibility for experimenting with different GNN variants or optimization techniques.

### 4.3.3 Data Flow

The flow of data begins with preprocessing the raw molecular data (SMILES strings), followed by feature extraction and conversion into graph representations. The model processes this graph data in layers, applying transformations and activations to progressively refine the prediction. During training, the model is optimized using backpropagation and an appropriate loss function. The final output is evaluated using standard performance metrics to ensure that the model is making accurate and reliable predictions.

The architecture also includes components for model evaluation, such as performance metrics and validation steps, ensuring that the model's predictions are both accurate and generalizable. The system is designed to be extensible, allowing for future improvements and integration of additional data sources or machine learning techniques.

### 4.3.4 Random Classifier Model

The **Random Classifier** was implemented as a baseline model to assess the performance of more advanced machine learning models in predicting bioactivity. The classifier works by randomly assigning class labels to each input sample, without considering any of the input features. This approach allows us to understand the baseline performance of the model, which can later be compared with more sophisticated models.

The implementation involves using the training data to fit the model (though no actual learning process occurs), and then the model randomly assigns class labels to the test data. The predicted labels are evaluated using standard performance metrics such as accuracy, precision, recall, F1-

score, and ROC-AUC. While the Random Classifier is expected to perform poorly compared to other machine learning models, it serves as an important benchmark to gauge the improvement achieved by more complex models.




Fig 4.2 Random Forest Model

### 4.3.5 GNN Model

The Graph Neural Network (GNN) was implemented to model the relationships between molecules in our drug discovery project. Unlike traditional machine learning models that treat data as feature vectors, GNNs are designed to process data represented as graphs, where nodes represent atoms and edges represent bonds between them. This structure makes GNNs well-suited for molecular data, as they can effectively capture the complex interactions and dependencies between atoms in a molecule.

The GNN implementation utilizes a multi-layer architecture, typically involving Graph Convolutional Networks (GCNs). The first step in the model is the graph convolution operation, which aggregates information from neighbouring nodes (atoms) to update the node

features (atom representations). This operation is repeated through multiple layers to capture higher-order interactions. After applying these graph convolution layers, the node features are pooled to obtain a graph-level representation, which is then passed through a fully connected layer to predict the target bioactivity.

The model's performance is evaluated using metrics like accuracy, precision, recall, and ROC-AUC. By comparing the performance of the GNN with baseline models, such as the Random Classifier, we aim to demonstrate its ability to capture meaningful patterns from the molecular graphs and provide more accurate predictions for drug discovery tasks.




Fig 4.3 Neural Network Architecture

# CHAPTER 5- PERFORMANCE ANALYSIS

## 5.1 Introduction

Performance analysis in this project focuses on evaluating the efficiency and accuracy of the machine learning model developed for drug discovery. The goal is to assess how well the model predicts molecular bioactivity and its ability to generalize across different datasets. Key metrics such as accuracy, precision, recall, and F1 score are used to measure the model's performance. Additionally, computational efficiency is evaluated in terms of training time, memory usage, and inference speed. This analysis helps identify areas for improvement and ensures that the model meets the desired standards for real-world applications.

## 5.2 Data

- **Data:** The dataset used for the drug discovery project primarily consists of molecular data, including features that represent molecular structures and properties. These features are typically derived from chemical descriptors, such as molecular weight, hydrophobicity, and topological indices, as well as from SMILES (Simplified Molecular Input Line Entry System) strings, which are used to encode the chemical structure of molecules.
- **Source of Data:**

  The dataset is obtained from publicly available repositories such as ChEMBL or other relevant chemical databases. ChEMBL provides bioactivity data for a wide range of compounds, including their interaction with specific targets, which is essential for predicting the effectiveness of drugs.
  The dataset includes molecular descriptors as input features and bioactivity values (such as IC50, EC50, or binding affinity) as output labels.

- **Preprocessing:**
  SMILES strings are converted into graph representations of molecules.

Feature engineering is applied to generate numerical descriptors that can be used as inputs to the machine learning model.

Data is split into training, validation, and test sets for model evaluation.

## 5.3 Evaluation Metrics:

To assess the performance of the machine learning model in predicting bioactivity, the following evaluation metrics are used:

1. Accuracy:

   Measures the percentage of correctly predicted instances out of the total number of predictions. This is a basic but important metric for overall model performance.

2. Precision:

   The ratio of true positive predictions to the total number of positive predictions. Precision is useful when the cost of false positives is high (e.g., predicting a molecule is bioactive when it isn't).

3. Recall (Sensitivity):

   The ratio of true positive predictions to the total number of actual positive instances. Recall is critical when the cost of false negatives is high (e.g., missing a bioactive compound).

4. F1-Score:

   The harmonic mean of precision and recall. It is a balanced metric that considers both false positives and false negatives, making it particularly useful when the class distribution is imbalanced.

5. ROC-AUC (Receiver Operating Characteristic - Area Under Curve):

   A performance measurement for classification problems at various thresholds settings. The ROC curve plots the true positive rate against the false positive rate, and the AUC represents the probability that the model ranks a random positive instance higher than a random negative instance.

6. Mean Squared Error (MSE):

   If the bioactivity prediction is a continuous value, MSE is used to measure the average squared difference between the predicted and actual values. This metric is essential for regression tasks.

7. Training Time and Inference Speed:

   These performance indicators measure the efficiency of the model. Training time is the duration needed to train the model, and inference speed refers to how quickly the model can make predictions on new data.

## 5.4 Results

The performance of the Graph Neural Network (GNN) model demonstrated a substantial improvement over the Random Classifier. The GNN model achieved an accuracy of 87.9%, significantly higher than the 75% accuracy of the Random Classifier. This reflects the GNN's ability to effectively analyze and classify molecular data, utilizing its graph-based architecture to capture intricate relationships within the molecules. The higher accuracy indicates that the GNN is more capable of distinguishing between active and inactive molecules, validating its effectiveness in the drug discovery task.

## 5.5 Visualisations

The visualizations of the evaluation results provide a clear and intuitive understanding of the model's performance. By illustrating key metrics such as accuracy, the effectiveness of the Graph Neural Network (GNN) is visually highlighted in comparison to the Random Classifier. These visuals not only showcase the model's prediction capabilities but also offer insights into how well the GNN captures complex patterns in molecular data, further emphasizing its potential in drug discovery.

### 5.5.1 Random Classifier

The Random Classifier visualization illustrates the baseline performance of a model that makes predictions purely based on random chance, serving as a point of comparison for evaluating the effectiveness of more sophisticated models like the GNN.




Fig 5.1 RC Molecular Descriptors




Fig 5.2 RC Confusion Matrix

### 5.5.2 Graph Neural Network

The GNN visualization highlights the model's performance in predicting outcomes based on graph-structured data, showcasing its ability to capture complex relationships between molecules and their properties, and demonstrating its superior performance compared to simpler models like the Random Classifier.




Fig 5.3 GNN Layer Activation




Fig 5.4 GNN Model Training




Fig 5.5 GNN Molecular Fingerprints




Fig 5.6 GNN Model Performance




Fig 5.7 GNN Confusion Matrix




Fig 5.8 GNN ROC Curve




Fig 5.9 GNN Precision Recall Curve

## 5.6 Conclusion

In conclusion, the performance analysis of the Random Classifier and GNN model demonstrates the effectiveness of graph-based approaches for drug discovery tasks. While the Random Classifier provided a baseline performance, the GNN model outperformed it by leveraging the inherent structure of molecular data, showcasing higher accuracy and the ability to capture complex relationships. This confirms that machine learning models, particularly GNNs, can significantly enhance prediction accuracy in drug discovery, making them a valuable tool for identifying potential drug candidates.

# CHAPTER-6 FUTURE ENHANCEMENT AND CONCLUSION

## 6.1 Introduction

Future enhancements to this project could involve exploring more advanced machine learning techniques, such as deep learning models, to further improve prediction accuracy. Additionally, incorporating larger, more diverse datasets could provide a broader scope and enhance the generalization of the model. Experimenting with different graph neural network architectures, optimizing hyperparameters, and integrating additional molecular descriptors could also lead to better model performance. Furthermore, integrating real-time data and refining the user interface for more interactive experiences could improve the practical application of the model in the drug discovery process.

## 6.2 Limitations/Constraints of the System

The following are some of the limitations and constraints of the proposed system:

- **Data Quality and Availability**: The accuracy of the model is limited by the quality and quantity of the available data. Incomplete or biased data can reduce performance.
- **Computational Resources**: Training complex models like GNNs requires significant computational power, which may be a constraint if resources are limited.
- **Model Complexity**: Graph neural networks, while powerful, may suffer from overfitting or increased training time if not properly optimized.
- **Scalability**: As the size of the dataset grows, the system may face challenges in maintaining efficiency and performance, requiring additional optimization.
- **Interpretability**: GNNs and other deep learning models can be hard to interpret, making it difficult to understand the reasoning behind specific predictions.

## 6.3 Future Enhancements

Future enhancements could involve:

- **Quantum Computing Integration**: Leveraging quantum computing to handle complex molecular simulations and drastically improve prediction speed and accuracy.

- **Automated Drug Design**: Implementing fully automated drug design pipelines powered by AI to suggest novel compounds for testing based on model predictions.
- **Explainable AI (XAI)**: Integrating advanced explainability features to make the model's predictions more transparent, enhancing trust and interpretability for researchers.
- **Multi-Omics Data Integration**: Incorporating multi-omics data (genomics, proteomics, etc.) to provide a more comprehensive view of drug-target interactions and improve predictive power.

## 6.4 Conclusion

This report has reviewed the state of the art in ML for rainfall forecasting and climate assessment, identified the key challenges and opportunities, and provided recommendations for future research and development. The report has also proposed a system architecture for integrating ML into rainfall forecasting and climate assessment systems, and discussed the hardware and software requirements for such a system.

# REFERENCES


1. **Cheng, F., Li, W., Zhou, Y., Shen, J., Wu, Z., & Li, J. (2012).** *AdmetSAR: A comprehensive source and free tool for evaluation of chemical ADMET properties*. Journal of Chemical Information and Modeling, 52(11), 3099-3105.
2. **Vamathevan, J., Clark, J., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., ... & Vandeputte, A. (2019).** *Applications of machine learning in drug discovery and development*. Nature Reviews Drug Discovery, 18(6), 463-477.
3. **Benedetti, P., & Ricci, C. (2019).** *Deep learning models for drug discovery*. Computational and Structural Biotechnology Journal, 17, 647-656.
4. **Stokes, J. M., Yang, K. K., Swanson, K., Jin, W., Cubillos-Ruiz, A., & Wacker, M. (2020).** *A deep learning approach to antibiotic discovery*. Cell, 180(4),688-702.
5. **Wang, Y., Wang, Z., Zhang, X., & Li, T. (2019).** *The application of machine learning in drug discovery*. Journal of Pharmaceutical Sciences, 108(1), 1-10.
6. **Bajusz, D., Rácz, A., & Héberger, K. (2015).** *Why is Tanimoto index the most popular similarity measure for molecular fingerprints?* Journal of Chemical Information and Modeling, 55(10), 1977-1985.
7. **Kuhn, M., & Johnson, A. (2013).** *Applied Predictive Modeling*. Springer.
8. **Goh, G. B., Hodas, N. O., & Vishnu, A. (2017).** *Deep learning for drug discovery*. Molecular Informatics, 36(11), 1700097.